Who Owns Radiometer?

Radiometer operates under Danaher Corporation's sustainability framework. Danaher has committed to reducing greenhouse gas emissions, water usage, and waste generation across its operations. The company's sustainability goals include integrating product sustainability into annual strategy planning processes.

Radiometer is working to improve the environmental footprint of its blood gas analyzers and point-of-care testing devices. Initiatives include reducing energy consumption in analyzers, minimizing waste from consumables like blood gas cartridges, and developing more sustainable packaging for reagents and calibration solutions.

As part of Danaher, Radiometer adheres to strict ethical standards and compliance programs. Danaher maintains comprehensive codes of conduct and compliance systems that apply to all subsidiary operations, ensuring ethical business practices in medical device manufacturing and sales.

Radiometer contributes to healthcare access through its point-of-care testing solutions. HemoCue products, in particular, enable diagnostic testing in resource-limited settings where traditional laboratory infrastructure is unavailable, supporting healthcare delivery in underserved communities and developing countries.

Danaher maintains supplier responsibility programs that ensure ethical sourcing and manufacturing practices throughout the supply chain. Radiometer works with suppliers who meet quality and ethical standards for medical device components and materials.

Radiometer's introduction of the world's first commercially available blood gas analyzer in 1954 remains one of the most significant innovations in acute care medicine. The collaboration with Poul Astrup established blood gas analysis as a standard of care in intensive care medicine, and this contribution continues to be recognized in medical literature and by professional associations in critical care medicine and respiratory therapy.

In July 2024, Danaher announced two new Centers of Innovation in Diagnostics to advance precision medicine development. These centers bring together technologies from multiple Danaher subsidiaries, including Radiometer, under CLIA and CAP-certified laboratory settings.

Radiometer's ABL blood gas analyzers are considered standard equipment in intensive care units worldwide. The brand's leadership position in acute care diagnostics reflects industry recognition of product quality and reliability built over seven decades.

Danaher has been recognized for its overall excellence in medical technology and diagnostics innovation. The Danaher Business System has been acknowledged as a best practice in operational excellence and continuous improvement methodology.

Radiometer Medical ApS has issued FDA recalls for specific blood gas analyzer models. The California Department of Public Health has documented FDA recalls for Radiometer ABL90 Flex and Flex Plus analyzers, as well as ABL800 Flex systems. These recalls were initiated to address potential device malfunctions or performance issues that could affect test accuracy. Medical device recalls are common in the diagnostics industry, with the FDA monitoring approximately 200,000 medical devices and nearly 4,000 devices requiring recalls from 2020 to 2024 across the industry.

Radiometer must comply with stringent regulatory requirements for in vitro diagnostic devices, including FDA clearance or approval in the United States and CE marking in Europe under the In Vitro Diagnostic Regulation (IVDR). These requirements create ongoing compliance obligations and quality system requirements. The European IVDR, which took full effect in 2024, imposed stricter requirements on diagnostic device manufacturers and required recertification of many devices.

Like all medical device manufacturers, Radiometer faces challenges in maintaining consistent quality across complex analytical instruments. The company must adhere to Good Manufacturing Practices (GMP) and maintain comprehensive quality management systems. Product recalls, while not unusual for medical device companies, can affect customer confidence and require corrective actions.

Radiometer operates in a competitive diagnostics market facing pressure from well-resourced competitors including Instrumentation Laboratory (Werfen), Siemens Healthineers, and Abbott Diagnostics. Healthcare budget constraints in many countries drive hospitals to seek lower-cost diagnostic solutions and negotiate more aggressively on instrument and reagent pricing, which can compress margins.